Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2024 | $30.00 → $35.00 | Buy | H.C. Wainwright |
| 3/28/2024 | $30.00 | Strong Buy | Raymond James |
| 10/25/2023 | $20.00 | Hold → Buy | Jefferies |
| 4/3/2023 | $26.00 | Overweight | Piper Sandler |
| 9/19/2022 | $30.00 | Buy | H.C. Wainwright |
| 7/12/2022 | $20.00 | Buy | Truist |
| 3/23/2022 | $24.00 | Buy | H.C. Wainwright |
| 12/22/2021 | $52.00 → $28.00 | Buy → Hold | Jefferies |
Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 100,500 shares of its common stock to four newly hired employees, consisting of inducement stock options to purchase an aggregate of 57,429 shares of common stock and inducement restricted stock units, covering an aggregate of 43,071 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth
- Preclinical data show that SRK-439 increased lean mass and lowered fat mass gain in mice receiving metformin - Data support that Scholar Rock's unique approach to selective myostatin inhibition could improve body composition in people living with obesity and on an existing background treatment - Scholar Rock's industry-leading anti-myostatin portfolio includes SRK-439 and apitegromab, the first investigational anti-myostatin therapy to show improved motor function in Spinal Muscular Atrophy (SMA) in a Phase 3 trial - Obesity program progressing with Phase 2 EMBRAZE trial on track for readout in Q2 2025 Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advan
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024, at 8:15am ET. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Scholar Rock website at http://investors.scholarrock.com. To pa
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
HC Wainwright & Co. analyst Andres Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $30 price target.
The trial will also evaluate the effects of apitegromab on the durability of weight loss upon withdrawal of GLP-1 RA therapy. The results from this trial will inform the development of SRK-439, a novel investigational selective myostatin inhibitor optimized for the treatment of cardiometabolic disorders, including obesity.
BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $29 to $31.
- Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co
10-Q - Scholar Rock Holding Corp (0001727196) (Filer)
8-K - Scholar Rock Holding Corp (0001727196) (Filer)
424B5 - Scholar Rock Holding Corp (0001727196) (Filer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
H.C. Wainwright reiterated coverage of Scholar Rock with a rating of Buy and set a new price target of $35.00 from $30.00 previously
Raymond James initiated coverage of Scholar Rock with a rating of Strong Buy and set a new price target of $30.00
Jefferies upgraded Scholar Rock from Hold to Buy and set a new price target of $20.00
Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 100,500 shares of its common stock to four newly hired employees, consisting of inducement stock options to purchase an aggregate of 57,429 shares of common stock and inducement restricted stock units, covering an aggregate of 43,071 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth
- Reported positive topline data from pivotal Phase 3 SAPPHIRE trial evaluating apitegromab in patients with Spinal Muscular Atrophy (SMA), achieving primary endpoint - On track to submit a U.S. Biologics License Application (BLA) and European Union marketing authorisation application (MAA) in 1Q 2025 - Phase 2 EMBRAZE trial enrollment completed for apitegromab in obesity with topline data expected in 2Q 2025 - Successful completion of upsized $345 million public offering to fund planned commercial launch in SMA and continue to advance priority programs - Management to host update call today at 8:15 a.m. ET Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused
- Preclinical data show that SRK-439 increased lean mass and lowered fat mass gain in mice receiving metformin - Data support that Scholar Rock's unique approach to selective myostatin inhibition could improve body composition in people living with obesity and on an existing background treatment - Scholar Rock's industry-leading anti-myostatin portfolio includes SRK-439 and apitegromab, the first investigational anti-myostatin therapy to show improved motor function in Spinal Muscular Atrophy (SMA) in a Phase 3 trial - Obesity program progressing with Phase 2 EMBRAZE trial on track for readout in Q2 2025 Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advan